Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (182)

« Back to Publications

Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.

Czajka-Francuz P. et al, (2026), Br J Cancer

Beyond data and technology: the need for new thinking to enable the era of precision prevention.

Tsakiroglou M. et al, (2026), BMC Med

Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours.

Glasspool R. et al, (2026), Invest New Drugs

The circulating proteome and cancer risk: a systematic literature review and meta-analysis of 26 prospective studies with genetic validation.

Dillman A. et al, (2026), EBioMedicine, 124

Housing and health inequalities: why is housing on the periphery of health and welfare policy?

Harding A. et al, (2026), Frontiers in Environmental Health, 5

Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.

Kazmi F. et al, (2025), Clin Oncol (R Coll Radiol), 48

A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.

Sooi K. et al, (2025), Br J Cancer, 133, 896 - 908

Precision Prevention Studies: A Targeted Approach to Cancer Prevention.

Blagden SP. et al, (2025), Cancer Prev Res (Phila), 18, 499 - 507

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.

Plummer R. et al, (2025), Cell Rep Med, 6

Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.

Kazmi F. et al, (2025), Cochrane Database Syst Rev, 3

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.

Liu J. et al, (2025), J Clin Oncol, 43, 735 - 747

LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorder.

Chettle J. et al, (2024), HGG Adv, 5

Access divergence to new cancer medicines in the United Kingdom.

Lythgoe MP. et al, (2024), Eur J Cancer, 207

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).

Spiliopoulou P. et al, (2024), J Exp Clin Cancer Res, 43

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.

Janku F. et al, (2024), Cancers (Basel), 16

Load More

1
2
3
4
5
6
7
...
»